BACKGROUND AND OBJECTIVES: Besides allergic reactions, antibodies against polyethylene glycol (PEG) have been associated with reduced PEG-asparaginase (PEG-ASNase) activity. Population pharmacokinetics (popPK) allow for an in-depth investigation of the influence of anti-PEG antibodies on PEG-ASNase pharmacokinetics. METHODS: PEG-ASNase activity (6261 samples) and anti-PEG antibodies (2082/6412 samples prior to/post administration) in 1444 children with acute lymphoblastic leukaemia treated in the AIEOP-BFM ALL 2009 trial were evaluated. Patients received two doses of PEG-ASNase during induction (2500 U/m2, intravenous, biweekly) and a third dose during reinduction treatment. Anti-PEG IgG and IgM measured prior to and post administration were explored for their influence on the initial clearance of PEG-ASNase using a previously established popPK model. Categorical and continuous antibody data, including each isotype individually as well as in combination, were assessed. RESULTS: High pre-existing levels of anti-PEG antibodies increase the initial drug clearance. Analysed separately, both anti-PEG IgGprior and IgMprior were significant covariates; the stronger effect was observed for anti-PEG IgMprior. Hockey stick models best described the data. For anti-PEG IgMprior, each additional log unit above the estimated cut point was related to a 41.4% increase in initial clearance after the first dose in induction. Antibody levels below the cut point were not associated with an effect on clearance. The combination of both isotypes did not provide additional information compared to anti-PEG IgMprior alone. Antibody levels post administration were not associated with an effect on clearance. CONCLUSION: Pre-existing antibodies against PEG-ASNase significantly increased the initial clearance in a subgroup of patients showing high antibody levels. (Trial registration: EU clinical trials register; EudraCT No: 2007-004270-43; first registered 23 October 2009.).

Biochemistry Department and Cancer Centre for Children The Children's Hospital at Westmead Westmead NSW Australia

Department of Paediatric Haematology and Oncology Charles University and University Hospital Motol Prague Czech Republic

Department of Paediatric Haematology and Oncology University Children's Hospital Muenster Albert Schweitzer Campus 1 A1 48149 Muenster Germany

Department of Paediatrics Christian Albrechts University Kiel and University Medical Centre Schleswig Holstein Kiel Germany

Faculty of Health and Medicine University of Sydney Sydney NSW Australia

Paediatric Haematology‑Oncology Unit Department of Paediatrics University of Milano Bicocca MBBM Foundation ASST Monza Monza Italy

Zobrazit více v PubMed

Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16(16):1677–1690. doi: 10.1016/S1470-2045(15)00363-0. PubMed DOI

Tram Henriksen L, Gottschalk Højfeldt S, Schmiegelow K, et al. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-pharmacokinetics and antibody formation. Pediatr Blood Cancer. 2017 doi: 10.1002/pbc.26686. PubMed DOI

Rizzari C, Lanvers-Kaminsky C, Valsecchi MG, et al. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica. 2019;104(9):1812–1821. doi: 10.3324/haematol.2018.206433. PubMed DOI PMC

Kloos RQH, Pieters R, Jumelet FMV, de Groot-Kruseman HA, van den Bos C, van der Sluis IM. Individualized asparaginase dosing in childhood acute lymphoblastic leukemia. J Clin Oncol. 2020;38(7):715–724. doi: 10.1200/JCO.19.02292. PubMed DOI

Maloney KW, Devidas M, Wang C, et al. Outcome in children with standard-risk B-cell acute lymphoblastic leukemia: results of children's oncology group trial AALL0331. J Clin Oncol. 2020;38(6):602–612. doi: 10.1200/JCO.19.01086. PubMed DOI PMC

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214–221. doi: 10.1038/nrd1033. PubMed DOI

Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer. 2007;110(1):103–111. doi: 10.1002/cncr.22739. PubMed DOI

Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019;37(23):2051–2061. doi: 10.1200/JCO.18.02439. PubMed DOI PMC

Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther. 2006;8(1):R12. doi: 10.1186/ar1861. PubMed DOI PMC

Hershfield MS, Ganson NJ, Kelly SJ, Scarlett EL, Jaggers DA, Sundy JS. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther. 2014;16(2):R63. doi: 10.1186/ar4500. PubMed DOI PMC

Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384(9937):37–44. doi: 10.1016/S0140-6736(13)61841-3. PubMed DOI PMC

Khalil A, Würthwein G, Golitsch J, et al. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. Haematologica. 2020 doi: 10.3324/haematol.2020.258525. PubMed DOI PMC

van der Sluis IM, Vrooman LM, Pieters R, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279–285. doi: 10.3324/haematol.2015.137380. PubMed DOI PMC

Tong WH, Pieters R, Kaspers GJL, et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood. 2014 doi: 10.1182/blood-2013-10-534347. PubMed DOI PMC

Ko RH, Jones TL, Radvinsky D, et al. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: a children's oncology group report. Cancer. 2015;121(23):4205–4211. doi: 10.1002/cncr.29641. PubMed DOI PMC

Würthwein G, Lanvers-Kaminsky C, Siebel C, et al. Population pharmacokinetics of PEGylated asparaginase in children with acute lymphoblastic leukemia: treatment phase dependency and predictivity in case of missing data. Eur J Drug Metab Pharmacokinet. 2021;46(2):289–300. doi: 10.1007/s13318-021-00670-8. PubMed DOI PMC

Würthwein G, Lanvers-Kaminsky C, Hempel G, et al. Population pharmacokinetics to model the time-varying clearance of the PEGylated Asparaginase Oncaspar® in children with acute lymphoblastic leukemia. Eur J Drug Metab Pharmacokinet. 2017;42(6):955–963. doi: 10.1007/s13318-017-0410-5. PubMed DOI

Wählby U, Thomson AH, Milligan PA, Karlsson MO. Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol. 2004;58(4):367–377. doi: 10.1111/j.1365-2125.2004.02170.x. PubMed DOI PMC

Icon Development Solutions. NONMEM users’s guides. Ellicott City, MD: Icon Development Solutions; 2009.

R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021.

RStudio Team. RStudio: integrated development environment for R. Boston, MA, USA: RStudio, Inc.; 2021.

Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241–57. 10.1016/j.cmpb.2005.04.005. PubMed

Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50. 10.1038/psp.2013.24. PubMed PMC

Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91–01. Blood. 2001;97(5):1211–1218. doi: 10.1182/blood.v97.5.1211. PubMed DOI

Abshire TC, Pollock BH, Billett AL, Bradley P, Buchanan GR. Weekly polyethylene glycol conjugated l-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 2000;96(5):1709–15. 10.1182/blood.V96.5.1709. PubMed

Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol. 2020;38(17):1897–1905. doi: 10.1200/JCO.19.03024. PubMed DOI PMC

Gottschalk Højfeldt S, Grell K, Abrahamsson J, et al. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia. Blood. 2021;137(17):2373–2382. doi: 10.1182/blood.2020006583. PubMed DOI

Kloos RQH, Uyl-de Groot CA, van Litsenburg RRL, Kaspers GJL, Pieters R, van der Sluis IM. A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 doi: 10.1002/pbc.26651. PubMed DOI

Kloos RQH, Mathôt R, Pieters R, van der Sluis IM. Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model. Haematologica. 2020 doi: 10.3324/haematol.2019.242289. PubMed DOI PMC

Poppenborg SM, Wittmann J, Walther W, et al. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice. Eur J Pharm Sci. 2016;91:122–130. doi: 10.1016/j.ejps.2016.06.007. PubMed DOI

Edlund H, Steenholdt C, Ainsworth MA, et al. Magnitude of increased infliximab clearance imposed by anti-infliximab antibodies in Crohn's disease is determined by their concentration. AAPS J. 2017;19(1):223–233. doi: 10.1208/s12248-016-9989-8. PubMed DOI

Mondelaers V, Ferster A, Uyttebroeck A, et al. Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium. Br J Haematol. 2020;190(1):105–114. doi: 10.1111/bjh.16495. PubMed DOI